Medicure

Medicure Inc. is a cardiovascular drug discovery and development Company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine, the largest pharmaceutical sector with annual global sales of over US $70 billion. Medicure was founded in 1997 by the renowned cardiovascular researcher, Naranjan S. Dhalla, Ph.D., Professor and Director, Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, University of Manitoba and by internationally recognized biotech entrepreneur, Albert D. Friesen, Ph.D. (President and CEO). Medicure became a public company in November 1999 and trades under the symbol MPH on the Toronto Stock Exchange (TSX) and MCU on the American Stock Exchange (Amex).

Contact Details: 4-1200 Waverley Street Winnipeg Manitoba R3T 0P4 Canada Tel: 204.487.7412 Fax: 204.488.9823 Email: info@medicure.com WWW: www.medicure.com/

Loading...

Recent Publications by Medicure:
Design and synthesis of novel pyridoxine 5'-phosphonates as potential antiischemic agents. On the basis of previous reports that the natural cofactor pyridoxal...	10th September, 2003	Medicure Inc. and CanamBioresearch Inc., 6-1200 Waverley Street, Winnipeg,	J Med Chem. 2003 Aug 14;46(17):3680-7. DOI Direct Link

Press Releases on Medicure:
Reportlinker Adds Germany Wound Care Management Market Analysis and Forecasts to 2015	8th October, 2009	Reportlinker	NEW YORK, Oct. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Germany Wound Care Management Market Analysis and
Kay Renz Steps into PR Position for Cosmetic Foot, Leg and Vein Doctor, Jodi Schoenhaus	12th January, 2009	Kay Renz Public Relations	Watch Dr. Schoenhaus Perform Foot Fat Pad Restoration on The Balancing Act on Lifetime Television BOCA RATON, Fla., Jan. 12 /PRNewswire/ -- "Walk with comfort and look great doing it" is
Robust Sales of Integrilin, ReoPro and Aggrastat Will Drive the Unstable Angina/Non-ST-Elevation Myocardial Infarction Drug Market	9th September, 2008	Decision Resources	WALTHAM, Mass., Sept. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts robust sales growth in

BioNews Results for Medicure:
Medicure Announces First Quarter Fiscal 2010 Financial Results	Therapeutics Daily:  Oct 15 2009 6:30AM Matching: medicure
Medicure Inc. (MCU) Announces First Quarter Fiscal 2010 Financial Results	BioSpace:  Oct 15 2009 6:43PM Matching: medicure
Medicure announces results of operations for the three months ended August 31, 2009	News-Medical.Net:  Oct 15 2009 6:47AM Matching: medicure
Medicure Announces First Quarter Fiscal 2010 Financial Results	Genetic Engineering News:  Oct 15 2009 12:05AM Matching: medicure

Medicure Patents:
US Patent No.	Title
7459468	Aryl sulfonic pyridoxines as antiplatelet agents
6861439	Treatment of cerebrovascular disease
6780997	Cardioprotective phosphonates and malonates
6677356	Treatment of cardiovascular and related pathologies
6667315	Cardioprotective phosphonates and malonates
→View more Medicure patents.

Medicure (MCU) Financial information Links from Barchart
MCU Quote from from Barchart.com
MCU Chart from from Barchart.com
MCU Profile from from Barchart.com
MCU Opinion from from Barchart.com
→View more Medicure finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 387 times since April 2007, the link to the organisation's website has been followed 61 times

Search for more companies in Winnipeg

Search for more companies in Manitoba

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Medicure